- Previous Close
4.1100 - Open
4.1000 - Bid 3.0000 x 100
- Ask 5.0600 x 200
- Day's Range
3.9400 - 4.3300 - 52 Week Range
2.3200 - 19.5000 - Volume
322,533 - Avg. Volume
506,418 - Market Cap (intraday)
136.108M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.57
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
www.lexeotx.comRecent News: LXEO
View MorePerformance Overview: LXEO
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LXEO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LXEO
View MoreValuation Measures
Market Cap
136.11M
Enterprise Value
24.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.11%
Return on Equity (ttm)
-85.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-98.33M
Diluted EPS (ttm)
-3.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
121.52M
Total Debt/Equity (mrq)
8.49%
Levered Free Cash Flow (ttm)
-48.43M